[1] BARWICK B G, GUPTA V A, VERTINO P M, et al. Cell of origin and genetic alterations in the pathogenesis of multiple myeloma[J]. Front Immunol,2019,10:1121.
[2] TEFFERI A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management[J]. Am J Hematol,2021,96(1):145-162.
[3] SUBRAMANIAN R, BASU D, DUTTA T K. Significance of bone marrow fibrosis in multiple myeloma[J]. Pathology,2007,39(5):512-515.
[4] MALHOTRA J, KREMYANSKAYA M, SCHORR E, et al. Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia[J]. Clin Lymphoma Myeloma Leuk,2014,14(1):31-36.
[5] MEERKIN D, ASHKENAZI Y, GOTTSCHALK-SABAG S, et al. Plasma cell dyscrasia with marrow fibrosis. A reversible syndrome mimicking agnogenic myeloid metaplasia[J]. Cancer,1994,73(3):625-628.
[6] VANDERMOLEN L, RICE L, LYNCH E C. Plasma cell dyscrasia with marrow fibrosis. Clinicopathologic syndrome[J]. Am J Med,1985,79(3):297-302.
[7] ECONOMOPOULOS T, STATHAKIS N, PAPAGEORGIOU E, et al. Myeloproliferative disorder during the course of multiple myeloma[J]. Acta Haematol,1986,76(2/3):176-177.
[8] STEVENSON J P, SCHWARTING R, SCHUSTER S J. Analysis of clonality using X-linked polymorphisms in a patient with multiple myeloma and myelofibrosis[J]. Am J Hematol,1998,59(1):79-82.
[9] FAIRLEY G H, JACKSON D C, MCDONALD P. Osteosclerosis in myelomatosis[J]. Br J Radiol,1964,37:852-855.
[10] COUGHLIN C, GREENWALD E S, SCHRAFT W C, et al. Myelofibrosis associated with multiple myeloma[J]. Arch Intern Med,1978,138(4):590-592.
[11] KASIMIS B S, YEN-LIN R, NEIMAN R S. Multiple myeloma associated with myelofibrosis. Report of a case and literature review[J]. Oncology,1981,38(6):369-372.
[12] KAWAUCHI K, MORI H, SUGIYAMA H, et al. Multiple myeloma with coexistent myelofibrosis: improvement of myelofibrosis following recovery from multiple myeloma after treatment with melphalan and prednisolone[J]. Jpn J Med,1991,30(5):483-486.
[13] 刘亚琳,王玮,单林玲,等. 骨髓纤维化患者的临床特点和骨髓病理学特征分析[J]. 安徽医药,2015,19(12):2335-2338.
[14] BRUNNER A M, HOBBS G, JALBUT M M, et al. A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database[J]. Leuk Lymphoma,2016,57(5):1197-1200.
[15] GLEITZ H, BENABID A, SCHNEIDER R K. Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms[J]. Curr Opin Hematol,2021,28(5):364-371.
[16] GAU Y C, HSIAO H H, LIU Y C, et al. Case report of coexistence of myeloproliferative neoplasms and multiple myeloma[J]. Kaohsiung J Med Sci,2020,36(6):469-470.
[17] DUHRSEN U, UPPENKAMP M, MEUSERS P, et al. Frequent association of idiopathic myelofibrosis with plasma cell dyscrasias[J]. Blut,1988,56(3):97-102.
[18] KURODA J, MATSUMOTO Y, TANAKA R, et al. JAK2V617F-positive essential thrombocythemia and multiple myeloma with IGH/CCND1 gene translocation coexist, but originate from separate clones[J]. Acta Haematol,2008,120(3):177-181.
[19] WANG X, PRAKASH S, LU M, et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells[J]. J Clin Invest,2012,122(11):3888-3899.
[20] ANGONA A, ALVAREZ-LARRAN A, BELLOSILLO B, et al. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms[J]. Leuk Res,2016,48:11-15. |
